On Thursday, Following Stocks were among the “Top 100 Gainers” In U.S. Stock Exchange: Orexigen Therapeutics, (NASDAQ:OREX), Net Element International (NASDAQ:NETE), Cerus (NASDAQ:CERS), Pioneer Energy Services (NYSE:PES)
Orexigen Therapeutics, Inc. (NASDAQ:OREX) disclosed that the European Commission has granted marketing authorization for Mysimba™ (naltrexone HCl / bupropion HCl prolonged release) as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (≥18 years) with an initial Body Mass Index (BMI) of ≥ 30 kg/m2 (obese), or ≥ 27 kg/m2 to 2 (overweight) in the presence of one or more weight-related co-morbidities (e.g., type 2 diabetes, dyslipidaemia, or controlled hypertension). This authorization applies to all 28 European Union (EU) member states.
Orexigen Therapeutics, Inc. (NASDAQ:OREX) inclined 4.77%, and closed at $7.25. The company has the market capitalization of $897.04 million. The beta value of the stock is 2.56. On the other hand the stock’s volatility for the week is 8.42%, and for the month is 6.96%. The stock’s price to book ratio is $40.28, however price to sale ratio is $16.16. Analyst’s mean recommendation regarding this stock is 1.60. (Where 1=Buy, 5=Sale).
Orexigen Therapeutics, Inc. (OREX) a biopharmaceutical company, focuses on the growth of pharmaceutical product candidates for the treatment of obesity. Its product candidates include NB32, which has completed Phase III clinical trials and is being studied in a cardiovascular outcomes trial; and Empatic that has completed Phase II clinical trials.
Formerly On March 25, 2015 Net Element International Inc (NASDAQ:NETE) a worldwide technology provider of mobile payments and value-added transactional services, proclaimed the formation of a joint venture between the Company and UAE-based industry professionals to sell and deliver Net Element’s payment-as-a-service solutions to all Gulf Cooperation Council (“GCC”) states and India. The JV will be financed solely by the local partners, who will own 80% with the Company maintaining a 20% equity stake in the JV. Net Element will be the exclusive provider of payment services to the JV, which will in turn have the exclusive rights to sell Net Element’s services in the territory and market such services under Net Element’s brand.
Net Element International Inc (NASDAQ:NETE)’s shares picked up 4.73%, and closed at $1.33. The stock volatility for the week is 6.94%, while for the month remained 7.26%. The company holds consensus target price of $5.17.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed -1.00 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained -170.50%.
The mean recommendation of analysts for this stock is 2.00. (Where 1=Buy, 5=Sale).
Net Element International Inc (NETE) a technology company specializes in mobile commerce and payment processing for electronic commerce in the United States, Russia, and the Commonwealth of Independent States. It works in one segment, Transactional Processing and Mobile Payment Solutions.
Cerus Corporation (NASDAQ:CERS) promulgated that the first patient has been enrolled in its TReatment UsE (TRUE) study to make the INTERCEPT Blood System for platelets available to regions in the United States with outbreaks of chikungunya and dengue virus under an Expanded Access Investigational Device Exemption (IDE). The American Red Cross is producing INTERCEPT platelet components for the study, which is being conducted in Puerto Rico.
Cerus Corporation (NASDAQ:CERS) enhanced 4.73%, and closed at $4.21. The company holds the market capitalization of $400.67 million. For the last twelve months, the stock was able to keep return on equity at -82.20%, while return on assets at -49.90%, in response to its return on investment at -87.00%. Its 20-day moving average decreased -2.79%, below 50-day moving average of -16.61%, above 200-day moving average of -5.95% from the latest market price of $4.21. The mean recommendation of analysts for this stock is 1.50. (Where 1=Buy, 5=Sale).
Cerus Corporation (CERS) works as a biomedical products company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication and designed to target and inactivate blood-borne pathogens, including viruses, bacteria, and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products.
Pioneer Energy Services Corp (NYSE:PES) rose 4.52%, and closed at $5.32. The stock has the beta value of 2.53, and its volatility for the week is 7.00%, while for the month it is 7.01%. The company has the market capitalization of $339.79 million. The company holds the book value per share of 7.76, whereas cash per share is 0.55. Price to book ratio remained 0.69, while price to sale ratio is 0.32. Analysts mean recommendation for the stock is said to be 2.80 (where 1=Buy, 5=sale).
Pioneer Energy Services Corp (PES) along with its subsidiaries offers drilling services and production services to oil and gas exploration and production companies in the United States and Colombia. The company’s Drilling Services Segment provides contract land drilling services in Texas, North Dakota, Utah, Appalachia, and Colombia.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
